Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- AVXL +3%
M&A news:
- CSIQ +5% (receives preliminary, non-binding 'going-private' proposal letter from Chairman & CEO for $18.47/share), XYL +1.2% (to acquire Pure Technologies (PPEHF) for CAD $9.00 per share in cash)
Crypto-Currency related stocks trading higher in pre-mkt:
- RIOT +16%, MARA +10%, SSC +6%, XNET +4%, CBOE +2% (launched Bitcoin Futures last night)
Other news:
- BPMC +25.2% (reports new data from ongoing Phase 1 clinical trial of Avapritinib), ARGX +24.8% (reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113), BLUE +23.6% (presents New Data from Clinical Studies of LentiGlobin), CBIO +19.4% (presents interim Phase 1/2 CB 2679d/ISU304 results), VSTM +14.5% (reports clinical data from the Phase 3 DUO Study), AKTX +13.3% (Phase II COBALT trial of Coversin in patients with PNH met the primary endpoint), UTSI +10.5% (Tonghao (Cayman) Limited discloses 9.9% active stake), FATE +10.1% (treats first subject with FATE-NK100 in APOLLO study for recurrent ovarian cancer), OSTK +8.7% (Morgan Stanley discloses increased passive stake to 11.4% (prior less than 1%)), CAPR +7.3% (may be in sympathy with other biotech peers), TRIL +7.1% (presents new clinical data from ongoing Phase 1 a/b trials for its CD47-blocking agent TTI-621), KDMN +6.3% (reports updated positive Phase 2 Data on KD025), BMRN +6.2% (presents clinical data for Valoctocogene Roxaparvovec Gene Therapy), QURE +4.7% (presents non-clinical data of AMT-061; supports nonclinical comparability plan), CLNT +4.3% (enters into sale and purchase agreement to acquire 60% interest in 3D Discovery Co for $5.606/ share or approx HK$3.0 million), TRVG +3% (continued strength), IONS +3% (Ionis Pharma announces that Roche has exercised its option to license IONIS-HTT Rx), RETA +2.9% (presents interim data from the ongoing Phase 1b portion of the REVEAL study of omaveloxolone in combination with ipilimumab or nivolumab), CELG +2.7% (Celgene and bluebird bio (BLUE) report updated results from ongoing multicenter Phase 1 study of bb2121 Anti-BCMA CAR T Cell Therapy), GILD +1.5% (reports long-term data from pivotal ZUMA-1 Study of Yescarta), .
Analyst comments:
- SNSS +16.9% (upgraded to Outperform from Market Perform at Wells Fargo)
- SPWR +4.6% (upgraded to Outperform at Robert W. Baird)
- ORMP +2.5% (resumed with a Buy at B. Riley FBR, Inc.; tgt $20)
- FSLR +2.5% (upgraded to Outperform at Robert W. Baird)
- WM +1.7% (upgraded to Buy from Hold at Stifel)
- X +1.6% (upgraded to Hold from Sell at Axiom Capital)
- DVA +0.9% (upgraded to Buy from Neutral at Citigroup)